TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
*
Home
Press release
Mar 09, 2022 16:06 JST
Source:
Eisai
Eisai Certified as the 2022 Health and Productivity Management Outstanding Organization (White 500)
TOKYO, Mar 09, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been certified as the Health and Productivity Management Outstanding Organization in the large enterprise category (White 500) by Japan's Ministry of Economy, Trade and Industry and the Nippon Kenko Kaigi.
Under the Certified Health and Productivity Management Outstanding Organization Recognition Program, the Nippon Kenko Kaigi examines large enterprises, small and medium enterprises and other organizations engaging in initiatives for overcoming health-related challenges in regional communities or for promoting health-conscious activities led by the Nippon Kenko Kaigi. It recognizes outstanding enterprises engaging in efforts for health and productivity management by evaluating from a business-management perspective based on following criteria: "management philosophy and policies", "organized frameworks", "systems and implementation of measures", and "evaluation and improvement". Eisai exceeded the average of its industry peers in all criteria, receiving particularly high scores for such as the "information disclosure and dissemination to other companies" (in the criteria of management philosophy and policies), "well adopted by employees" (in the criteria of organized frameworks), "lifestyle improvement" and "other measures*" (in the criteria of systems and implementation of measures). The program was launched in 2017, and this is the fourth time that Eisai was certified as a "White 500" company.
Eisai issued the "Eisai Health Declaration" in 2019, and has strategically implemented health management for employees from a management perspective.
Eisai will continue to promote its efforts toward practicing the health and productivity management and to further contribute to increasing the benefits of patients and their families.
Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides. Eisai calls this philosophy the "human health care (hhc)" philosophy, in one word.
Eisai regards its employees as an important stakeholder and asset for the realization of its hhc philosophy.
Eisai believes that its commitment to maintaining and improving the health of human resources is fundamental to develop highly engaged employees who are motivated to contribute voluntarily toward the realization of the hhc philosophy.
*Measures to address health issues specific to women and the elderly, long working hours, mental health, dependents of the company's employees, and prevention of infectious disease during COVID-19 pandemic.
Media Inquiries:
Public Relations Department
Eisai Co., Ltd.
+81-(0)3-3817-5120
Source: Eisai
Sectors: Healthcare & Pharm
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Related Press Release
Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI(R)" for the Treatment of Early Alzheimer's Disease in Japan
November 28 2025 22:00 JST
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) IQLIK(TM) (lecanemabirmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
November 26 2025 18:42 JST
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom
November 17 2025 21:08 JST
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
October 30 2025 13:43 JST
Merck & Co., Inc. and Eisai Announce WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
October 28 2025 23:30 JST
Health Canada Grants Authorization for "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease
October 27 2025 13:23 JST
LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"
October 14 2025 16:54 JST
Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
October 08 2025 11:03 JST
Eisai Highlights Breadth of Oncology Research at ESMO 2025
October 03 2025 17:01 JST
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China
September 29 2025 09:33 JST
More Press release >>
Latest Press Release
Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI(R)" for the Treatment of Early Alzheimer's Disease in Japan
Nov 28, 2025 23:00 JST
JFCR, NEC, and Taiho to Develop Cancer Vaccines Utilizing Whole-Genome Information
Nov 28, 2025 19:41 JST
MHI Publishes "MHI REPORT 2025" and "SUSTAINABILITY DATABOOK 2025"
Nov 28, 2025 19:05 JST
Sharp Wins IAM's "Asia IP Elite 2025", Awarded to Companies with Outstanding Intellectual Property Strategy for The Second Consecutive Year
Nov 28, 2025 18:36 JST
Fujitsu builds platform for NSK to create environmental value throughout the product lifecycle of bearing products
Nov 28, 2025 18:01 JST
Fujitsu launches Japan Edition of SAP Fioneer Cloud for Insurance, a next-generation platform supporting core business operations in the Japanese insurance industry
Nov 28, 2025 17:28 JST
NEC Launches Sales Support Solution Utilizing Agentic AI
Nov 27, 2025 22:31 JST
Fujitsu and Yamaguchi University develop low-power edge computing technology for near real-time image processing on small satellites
Nov 27, 2025 22:00 JST
World's first ever spiral escalator renewal project conducted at a commercial facility in Mexico
Nov 27, 2025 11:00 JST
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) IQLIK(TM) (lecanemabirmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
Nov 26, 2025 19:42 JST
Fujitsu accelerates blue carbon certification with ocean digital twin technology
Nov 26, 2025 19:05 JST
Fujitsu recognized with two Microsoft Japan Partner of the Year awards
Nov 26, 2025 18:40 JST
Xforce HEV Model Wins Thailand Car of the Year 2025
Nov 26, 2025 18:00 JST
Mitsubishi Motors Launches the All-New Destinator in the Philippine Market
Nov 25, 2025 14:36 JST
New Corporate Slogan "In step with your future."
Nov 25, 2025 13:51 JST
MHI Receives EPC Contract for Cyclo Olefin Polymer Plant for Zeon Corporation
Nov 25, 2025 13:13 JST
DOCOMO Wins Gold Medal in Kaggle, the World's Largest AI Data Science Competition
Nov 22, 2025 00:39 JST
Fujitsu launches integrated package of core system support services for food distribution industry
Nov 22, 2025 00:04 JST
Special Autumn Event: "Anime Tokyo Station Autumn Festival"
Nov 20, 2025 13:00 JST
ANIME TOKYO STATION ON ROBLOX: New Game "ANIME SKILL TCG" Out Now!
Nov 20, 2025 11:00 JST
More Latest Release >>